CRISPR Therapeutics AG

🇺🇸NASDAQ Global Market
Back to all articles
CRISPR Therapeutics AG stock analysis CRSP overview
Somewhat Bullish +45

CRISPR Therapeutics (CRSP) Stock Could Be 69.5% Below Fair Value After Recent Gains - simplywall.st

📊 CRISPR Therapeutics (CRSP) is trading at US$54.09, which Simply Wall St's DCF model values as a 69.5% discount to a fair value of US$177.40.

📈 The stock has posted strong short-term performance with an 8.61% return over the last week and an 8.40% return over the last month.

💰 The company currently reports ongoing losses totaling US$568.534 million while generating revenue of US$4.1 million.

🔬 As a clinical-stage biotech, CRSP's valuation relies heavily on future cash flow projections rather than current net income or profitability.

📉 Analyst price targets are more conservative than the DCF model, with an average target of US$83.52 representing only a 54% discount to the current price.

⚠️ The valuation assumes successful development of the early-stage pipeline and favorable outcomes from upcoming trial data and regulatory milestones.

Bullish Signals
  • The stock exhibits strong short-term momentum with an 8.61% gain over the past week and an 8.40% gain over the past month.
  • Simply Wall St's discounted cash flow model estimates a fair value of US$177.40, implying the current price is significantly undervalued at a 69.5% discount.
  • The company has achieved a positive one-year total shareholder return of 22.24% despite being in a clinical-stage development phase.
Risk Factors
  • CRISPR Therapeutics reports substantial ongoing losses of US$568.534 million, indicating it is not yet profitable.
  • The company's current revenue is low at US$4.1 million, reflecting its early-stage commercial operations.
  • Analyst price targets are more cautious than the DCF model, with an average target of US$83.52 suggesting less optimism about immediate value realization.
  • The high valuation depends entirely on the successful development of an early-stage pipeline and favorable regulatory outcomes.
Full Analysis
Simply Wall St analysis suggests CRISPR Therapeutics (CRSP) shares are trading at US$54.09, representing a significant discount to its estimated fair value of US$177.40 based on a discounted cash flow (DCF) model projecting future cash flows. The stock has demonstrated solid short-term momentum with a 7-day return of 8.61% and a 30-day return of 8.40%, contributing to a one-year total shareholder return of 22.24%. However, the company currently reports ongoing losses of US$568.534 million and relies on the successful development of its early-stage pipeline. While the DCF model indicates the stock is undervalued by approximately 69.5%, analyst price targets present a more cautious outlook, with an average target of US$83.52 implying only a 54% discount to current prices. The article highlights the divergence between high-growth cash flow expectations and near-term profitability concerns typical for clinical-stage biotech firms. Investors are presented with a choice between trusting the higher DCF valuation driven by future revenue growth potential or the more conservative analyst consensus. The analysis notes that while the company focuses on gene editing medicines using its CRISPR/Cas9 platform, assumptions regarding trial data and regulatory milestones could quickly alter these underlying valuations.